Analyst Ratings for Sarepta Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided ratings for Sarepta Therapeutics (NASDAQ:SRPT) with 3 bullish, 5 somewhat bullish, and 2 indifferent ratings in the last quarter. The average price target is $122.9, representing an upside from the current price of $83.7. This target is a 23.0% decrease from the previous target of $159.62. Analysts' opinions can vary and are based on various data sources, including company calls, financial statements, and insider information.
November 21, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sarepta Therapeutics received mostly positive ratings from analysts, with an average price target of $122.9, suggesting a significant upside from the current price but a decrease from the previous target.
The positive analyst ratings and the higher price target compared to the current stock price suggest a potential upside, which could lead to short-term price appreciation. However, the decrease from the previous price target may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100